BioSpace News Archive

Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today reported financial results for the second quarter ended June 30, 2018 and provided a corporate update.

Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on the development of nervous system therapies based on its neural stem cell and small molecule compound technologies, today announced that the Board of Directors has appointed Jim Scully as interim chief executive officer.

Evolent Health, Inc. announced financial results for the quarter ended June 30, 2018.

Merck announced the retirement effective November 30, 2018 of its chief human resources officer Mirian M. Graddick-Weir, following 12 years of service with the company.

TRULANCE® second quarter net sales up over 40% versus prior quarter

Community Healthcare Trust Incorporated (NYSE: CHCT) (the “Company”) today announced results for the three months ended June 30, 2018.

REGENXBIO Inc. announced that its previously announced conference call and webcast on Wednesday, August 8, 2018 at 8:00 a.m. ET to discuss its financial results for the quarter ended June 30, 2018

Alternate Health Corp. announced that the Company signed a binding contract on August 6, 2018, to provide laboratory services for a large multistate laboratory provider.

The Pharmaceutical Care Management Association issued the following statement on today’s announcement by the Administration to reduce prescription drug costs in Medicare Part B.

On August 8, 2018 Beijing time I-Mab Biopharma and MorphoSys AG announced today that I-Mab has Submitted an investigational new drug (IND) application to China National Drug Administration (CNDA) for TJ202/MOR202, a human monoclonal antibody directed against CD38 for the treatment of multiple myeloma.